Tech Center 1600 • Art Units: 1631 1672 1685
This examiner grants 27% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19341734 | PLATFORMS, SYSTEMS, AND METHODS FOR PATHWAY OPTIMIZATION FOR PROCESS BOTTLENECKS IN SYNTHETIC BIOLOGY DEVELOPMENT | Non-Final OA | X Development LLC |
| 17745399 | NANOPORE SENSOR FOR ENZYME-MEDIATED PROTEIN TRANSLOCATION | Non-Final OA | The Regents of the University of California |
| 16803768 | UNSUPERVISED PROTEIN SEQUENCE GENERATION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17629327 | DETECTING NEURALLY PROGRAMMED TUMORS USING EXPRESSION DATA | Final Rejection | Genentech, Inc. |
| 16504469 | HIGHLY SENSITIVE SURVEILLANCE USING DETECTION OF CELL FREE DNA | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 17735117 | METHOD AND PROCESS FOR PREDICTING AND ANALYZING PATIENT COHORT RESPONSE, PROGRESSION, AND SURVIVAL | Final Rejection | Tempus AI, Inc. |
| 17571412 | SYSTEMS AND METHODS FOR JOINT LOW-COVERAGE WHOLE GENOME SEQUENCING AND WHOLE EXOME SEQUENCING INFERENCE OF COPY NUMBER VARIATION FOR CLINICAL DIAGNOSTICS | Non-Final OA | Tempus AI, Inc. |
| 16888357 | PAN-CANCER MODEL TO PREDICT THE PD-L1 STATUS OF A CANCER CELL SAMPLE USING RNA EXPRESSION DATA AND OTHER PATIENT DATA | Final Rejection | TEMPUS AI, INC. |
| 16732229 | TRANSCRIPTOME DECONVOLUTION OF METASTATIC TISSUE SAMPLES | Final Rejection | TEMPUS AI, INC. |
| 17762097 | Systems and Methods for the Efficient Identification and Extraction of Sequence Paths in Genome Graphs | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 17204892 | CELL-FREE DNA FOR ASSESSING AND/OR TREATING CANCER | Non-Final OA | The Johns Hopkins University |
| 17188737 | PEAK-PRESERVING AND ENHANCING BASELINE CORRECTION METHODS FOR RAMAN SPECTROSCOPY | Final Rejection | Virginia Tech Intellectual Properties, Inc. |
| 17502661 | METHOD AND APPARATUS FOR PROVIDING INFORMATION ASSOCIATED WITH IMMUNE PHENOTYPES FOR PATHOLOGY SLIDE IMAGE | Non-Final OA | LUNIT Inc. |
| 17725354 | Genome Feature Extraction Method, Disease Prediction Method, Apparatus and Device | Non-Final OA | Alibaba (China) Co., Ltd. |
| 16794696 | ALIGNMENT USING HOMOPOLYMER-COLLAPSED SEQUENCING READS | Final Rejection | Pacific Biosciences of California, Inc. |
| 17838115 | METHOD AND SYSTEM FOR IMPROVED MANAGEMENT OF GENETIC DISEASES | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17726250 | SYSTEM AND METHOD FOR GENE EDITING CASSETTE DESIGN | Non-Final OA | Inscripta, Inc. |
| 18369788 | SYSTEMS AND METHODS FOR ENGINEERING PROTEIN ACTIVITY | Final Rejection | Aether Biomachines, Inc. |
| 15489658 | METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES | Final Rejection | UNIVERSITY OF MARYLAND, BALTIMORE |
| 15028253 | METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES | Final Rejection | UNIVERSITY OF MARYLAND, Baltimore |
| 18118024 | FRAGMENTATION FOR MEASURING METHYLATION AND DISEASE | Final Rejection | Centre for Novostics Limited |
| 16721619 | CELL-FREE DNA END CHARACTERISTICS | Non-Final OA | GRAIL, Inc. |
| 17860782 | SOIL HEALTH INDICATORS USING MICROBIAL FUNCTIONAL GENES | Final Rejection | MIRATERRA INC. |
| 17613966 | SIMULATION OF TEMPERATURES IN THE BODY | Final Rejection | ELMEDIX NV |
| 17184505 | SYSTEMS AND METHODS FOR SEQUENCE DESIGN | Final Rejection | Baidu USA, LLC |
| 17709614 | SYSTEMS AND METHODS FOR GENERATING REPRODUCED ORDER- DEPENDENT REPRESENTATIONS OF A CHEMICAL COMPOUND | Final Rejection | Collaborative Drug Discovery, Inc. |
| 17639723 | METHOD FOR AUTOMATICALLY PREDICTING TREATMENT MANAGEMENT FACTOR CHARACTERISTICS OF DISEASE AND ELECTRONIC APPARATUS | Non-Final OA | PHIL RIVERS TECHNOLOGY, LTD. |
| 17587195 | WEB-BASED PHARMACOGENOMICS TOOL | Final Rejection | DASMAN DIABETES INSTITUTE |
| 17575894 | DYNAMICALLY RESIZED SLIDING WINDOW FOR VARIANT ANALYSIS | Final Rejection | Helix OpCo, LLC |
| 17556068 | METHODS AND SYSTEMS FOR IDENTIFYING TARGET GENES | Final Rejection | Algen Biotechnologies, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy